OHSR RESPONSE TO REQUEST FOR REVIEW OF RESEARCH ACTIVITY INVOLVING HUMAN SUBJECTS

To:	301-480-2198 Hesse, Bradfo NCI EPN 4068			Ε.	xempt: #:	5810
Fror	m: Office of Hum	nan Subjects Researc	h (OHSR)			
Th Ins (H wh	stitute (NCI) is pland INTS 4) over the contich the general pop	er Control and Popula ining to conduct data o ourse of three years s pulation uses commu	ation Sciences, Behavio collection for the Health starting in 2011. The pu nication channels to ob a resources while collec	Information Nation Irpose of HINTS is tain information al	onal Trends S s to assess th bout health ar	urvey 4 e ways in nd cancer.
Orig	inal Request Recei	ived in OHSR on:	6/9/2011			
Res	ponsible NIH Resea	arch Investigator(s):	Bradford Hesse, PhD	NCI		
OH	SR review of your r	equest dated Wed, Ju	un 1, 2011 has determi	ned that:		
	Federal regulations for the protection of human subjects do not apply to above named activity. The OHSR determination of Not Human Subjects Research is based on the interpretation of 45 CFR 46 under "Research Involving Coded Private Information or Biological Specimens" (OHRP, Revised October 16, 2008) and Guidance on Engagement of Institutions in Human Subjects Research (October 16, 2008). NOTIFY OHSR VIA AN E-MAIL AMENDMENT OF ANY CHANGES THAT MAY ALTER THIS RESEARCH ACTIVITY.					
	The activity is designated EXEMPT , and has been entered in the OHSR database. <u>PLEASE NOTIFY OHSR</u> OF ANY SIGNIFICANT CHANGES THAT MAY ALTER THE EXEMPT STATUS OF THIS RESEARCH ACTIVITY.					
	NOT EXEMPT. OHSR recommends IRB review. Please forward your request to the Chair of your IRB, who may ask you to provide additional information in order to determine whether expedited or full review is appropriate.					
	Confidentiality Agr	reement				
	Reliance					
	Amendment					
	Other					
Note		R 1-4	Office F	erson SPC	Admin Assis	st. CB
	arlotte ripiden, 3D		Acting Director, OHSR		6/21/2011 Date	<u> </u>
Don	nestic/International:					
Dor	nestic			OHSR Use Only	ı	
Human Subjects Data: Yes				3	5 🗆 6	
Biologic Material: No				- 	25-\$ V	

Appendix I: Westat IRB Approval Letter



An Employee-Owned Research Corporation

Memo

Date: November 11, 2010

To: Terisa Davis, Project Director

From: Kerry Levin; Chair, Westat IRB

Subject: Expedited Approval of HINTS, Project 8861.01.04

FWA 5551

As Chair of the Westat Institutional Review Board (IRB), I reviewed the materials submitted for the following: HINTS, Project 8861.01.04. The Westat IRB reviews all studies involving research on human subjects. This study is sponsored by the National Cancer Institute.

Keny Levin

The survey, that assesses the ways in which the general population uses communication channels to obtain information about health and cancer, may have several changes from the one conducted in 2008.

Westat will be responsible for the following activities:

- Mailings (Prenotification letter, thank you, and reminder post cards)
- Additional 5th mailing of Spanish materials
- Focus groups with eligible respondents (2 of these in Spanish)
- Cognitive testing:
 - O Two rounds per modular instrument
 - Testing with a total of 100 English and 50 Spanish-speakers (total of 150 cog interviews)
- Field test to be conducted prior to first cycle of data collection
 - o N=150
 - Conduct debriefing interviews with 20 of those that complete field test survey

Focus groups and cognitive tests will be either video or audio taped. Once notes are taken, tapes will be destroyed and names or identifiers will not be used in reports.

The data will be owned by NCI but will not be turned over until it has been de-identified.

IRB regulations permit expedited review of certain activities involving minimal risk [45 CFR pt. 46.110 (b) (1)]. This study can be considered minimal risk and is approved under expedited authority. A waiver of informed consent is also approved (45 CFR 46 116d) as the research involves

no more than minimal risk, the waiver or alteration will not adversely affect the rights and welfare of the subjects, and the research could not practicably be carried out without the waiver or alteration.

When ready, submit protocols and consent forms for focus groups and cognitive testing to the IRB.

Prior to fielding, submit final letters and instruments to the IRB for review and approval.

As the Project Director you are responsible for the following:

- If you received a conditional approval, project activities (e.g., recruiting, enrolling) <u>may not begin</u> until your responses have been received by the IRB and final approval is granted.
- You are required to submit this study for a continuing review on or before November 11, 2011.
- In the interim, you are responsible for notifying the IRB Office as soon as possible if there are any injuries to the subjects, problems with the study, or changes to the study design that relate to human subjects.

cc: Institutional Review Board Nancy Weinfield